Glaukos Co. (NYSE:GKOS) Shares Sold by Braidwell LP

Braidwell LP lessened its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 37.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 311,616 shares of the medical instruments supplier's stock after selling 184,960 shares during the quarter. Braidwell LP owned about 0.57% of Glaukos worth $40,597,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GKOS. Values First Advisors Inc. purchased a new position in shares of Glaukos in the third quarter valued at $25,000. Harvest Fund Management Co. Ltd lifted its holdings in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after buying an additional 860 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after buying an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos during the second quarter valued at about $187,000. Finally, KBC Group NV grew its stake in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at $4,225,345.12. This represents a 8.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Glaukos Stock Performance

Shares of NYSE:GKOS traded up $0.96 during trading on Friday, reaching $143.65. 165,871 shares of the company's stock traded hands, compared to its average volume of 570,121. The stock has a market capitalization of $7.92 billion, a P/E ratio of -47.62 and a beta of 1.02. Glaukos Co. has a 12 month low of $59.58 and a 12 month high of $146.86. The company has a 50 day moving average of $134.13 and a 200-day moving average of $124.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.50) earnings per share. On average, equities analysts expect that Glaukos Co. will post -1.91 EPS for the current year.

Analyst Ratings Changes

GKOS has been the subject of a number of analyst reports. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. Truist Financial upped their target price on Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Stifel Nicolaus raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Wells Fargo & Company increased their price objective on shares of Glaukos from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Finally, BTIG Research raised their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $135.45.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.